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PCV54
ECONOMIC EVALUATION OF ROSUVASTATIN
IN A NATURALISTIC SETTING
Jansen JP1, Goettsch WG2, van Loon J1, Herings RMC2
1Mapi Values, Houten, Netherlands; 2PHARMO Institute,
Utrecht, Netherlands
OBJECTIVE: To asses the cost-effectiveness of rosuvas-
tatin in comparison with simvastatin and atorvastatin for
the treatment of hypercholesterolemia in daily practice in
the Netherlands. METHODS: A cohort of statin users
was selected from the PHARMO database. Information
on cholesterol and medical resource utilization was
obtained from a clinical lab database. Information on
treatment patterns was obtained from GPs. Effectiveness
in daily practice, deﬁned as change in cholesterol level,
and achieving the NCEP ATP-II guideline was assessed at
3, 12, and 24 months. The ratio between efﬁcacy from
clinical trials and effectiveness in daily practice for sim-
vastatin and atorvastatin combined with the efﬁcacy of
rosuvastatin was used to estimate the effectiveness of
rosuvastatin in daily practice. With bootstrapping the
cost-effectiveness of rosuvastatin was estimated. RE-
SULTS: In daily practice it is expected that rosuvastatin
results in a larger reduction in total cholesterol and 
LDL-cholesterol, and a higher probability of achieving
the NCEP ATP-II guidelines than simvastatin and ator-
vastatin. For diabetes or arteriosclerosis patients the 
difference in predicted effectiveness was greater: The
probability of achieving the LDL-cholesterol threshold
for rosuvastatin was 63.9% (95% CI 46.5; 81.3), for sim-
vastatin 37.1% (95% CI 29.8; 46.0), and for atorvastatin
41.9% (95% CI 28.0; 62.5). Total medical costs from the
insurance perspective were €1471 for rosuvastatin, €1850
for simvastatin, and €1562 for atorvastatin over a 2-year
period. The probability that rosuvastatin is dominant
over simvastatin is more than 90%. The probability that
rosuvastatin is cost-effective in comparison to atorvas-
tatin varies between 60% and 80% depending on
outcome, willingness to pay, and risk proﬁle. CONCLU-
SION: It is expected that rosuvastatin in comparison to
simvastatin saves costs in combination with a greater
effectiveness in routine daily practice. The results indicate
that rosuvastatin is also cost-effective in comparison 
with atorvastatin. A greater beneﬁt was observed for
patients with diabetes and arteriosclerosis treated with 
rosuvastatin.
PCV55
“FAST-TRACKING” IN THE CARDIAC 
INTENSIVE CARE UNIT: A TRIAL-BASED
ECONOMIC EVALUATION OF THREE
SEDATION/ANALGESIA PROTOCOLS IN THE
MANAGEMENT OF PATIENTS FOLLOWING
CARDIAC SURGERY
Long KH, Oliver Jr WC, Mc Murtry EK,Abel M, Nuttall G,
Orszulak TA, Schaff HV, Schroeder DR, Ereth MH
Mayo Clinic, Rochester, MN, USA
OBJECTIVES: Recent pharmacologic advances in 
perioperative sedation and analgesia have enabled the
early extubation or “fast-tracking” of patients following
cardiac surgery in the intensive care unit (ICU). The clin-
ical and economic implications associated with these
sedation/analgesia protocols in practice, however, remain
unclear. We prospectively assessed the total costs of care
and length of stay associated with three sedation/analge-
sia protocols for use in technology assessment of alterna-
tive management strategies. METHODS: A total of 113
cardiac surgery patients were randomized to receive in a
double-blind manner either: propofol infusion with mor-
phine bolus (Group P, n = 41); fentanyl infusion with
midazolam (Group F, n = 34); or combined propofol and
fentanyl infusion (Group PF, n = 38) for sedation and
analgesia during intubation. We tracked resource utiliza-
tion in administrative data to estimate ICU-related phar-
macy costs, physician costs, hospital costs, total direct
medical costs, and length of stay. Standardized, nation-
ally representative cost estimates were used to value
resource utilization in 2002 constant dollars. We used
analysis of variance methods (ANOVA) to determine
whether observed economic outcomes differed between
sedation protocols. RESULTS: Mean observed ICU-
related length of stay (days) was similar overall between
groups (Group P: 1.14; Group F: 1.10; Group PF: 1.26;
p = 0.630) as were average total medical costs ($21,338
vs. $20,208 vs. $20,148, respectively; p = 0.466). Mean
pharmacy, physician, and hospital costs also did not sig-
niﬁcantly differ between groups (pharmacy costs: $1304
vs. $1302 vs. $1280, respectively; p = 0.976). Pair-wise
comparisons between sedation approaches also did not
reveal any signiﬁcant difference in economic outcomes
between management protocols. CONCLUSIONS: There
is no evidence of signiﬁcantly reduced length of stay or
total costs associated with propofol-based sedation/anal-
gesia protocols in practice. Additional research is war-
ranted to assess clinical outcomes associated with these
agents to guide clinical practice decision-making.
PCV56
ESTABLISHING THE COST-EFFECTIVENESS OF
STATINS IN THE PRIMARY PREVENTION OF
CHD USING A QUASI MARKOV MODEL
Dewilde S, Davies A, Hutton J
MEDTAP International, London, United Kingdom
OBJECTIVES: This model compares four statins (rosu-
vastatin, atorvastatin, simvastatin and pravastatin) in
their costs and effectiveness of primary prevention for
Coronary Heart Disease (CHD). The use of models are
increasingly accepted to determine the cost-effectiveness
of products. METHODS: A quasi-Markov model was
used to simulate the life-time experience of CHD events
(angina, Myocardial Infarction (MI), Cardio Vascular
Disease (CVD), death) for cohorts of patients classiﬁed
by age, gender, cholesterol level and risk factors. The
Framingham Risk Equations were used to calculate the
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risk of future CHD events and life expectancies from the
onset of CHD. Efﬁcacy parameters came from a com-
parative Phase III trial—study 25. Demographic variables
and economic variables (costs of initiating and maintain-
ing cholesterol-lowering therapy; the costs of managing
CHD events and the costs of the drug therapy) were taken
from published sources or calculated from unit costs 
and and the frequency of use of different services. A base
case analysis was constructed from the perspective of a
55-year-old male. Extensive sensitivity analysis was con-
ducted by varying the discount rates, drug prices,
maximum percentage of beneﬁts that could be achieved,
time delay in the onset of beneﬁts, and restricting the
analysis to 10 years to allow for lack of long-term adher-
ence. RESULTS: The incremental life years saved for
rosuvastatin, atorvastatin, simvastatin, and pravastatin
compared to no treatment for a 55-year-old male with 5.5
TC/HDL cholesterol ratio were 0.40, 0.33, 0.32, and
0.26 respectively. The associated incremental costs were
£2844, £2856, £3107, and £3889. Rosuvastatin domi-
nated the three other statins in the primary prevention of
CHD, for all ages and all cholesterol levels. Sensitivity
analysis conﬁrmed the results. CONCLUSIONS: In this
quasi-Markov model, rosuvastatin was shown to be more
cost-effective for the primary prevention of CHD events
than atorvastatin, simvastatin, and pravastatin.
PCV57
COST EFFECTIVENESS OF ANTIHYPERTENSIVE
THERAPY IN DIABETIC PATIENTS IN ITALY
Mantovani LG1, Bustacchini S2, Ruffo P2
1University of Milan, Milan, Italy; 2Pﬁzer Italia S.r.l, Rome, Italy
OBJECTIVE: There is evidence of substantial beneﬁt in
antihypertensive combination therapy in diabetic patients
compared to monotherapy. We evaluated the combina-
tion of low dose cilazapril plus low dose doxazosin (Cz
+ Dx) versus high dose cilazapril (Cz) and versus high
dose doxazosin (Dx) in hypertensive diabetic patients in
Italy. METHODS: An incremental cost effectiveness
analysis was conducted in the societal perspective, con-
sidering Health care and indirect costs of treating for 10
years a hypothetical cohort of 1000 male diabetics, aged
50–54 years with levels of systolic blood pressure (SBP)
above 160mmHg, with Cz + Dx vs Cz vs Dx. The effects
of considered drugs in lowering blood pressure were
derived from the study by Rachmani et al (Nephron,
1998). Effectiveness was assessed in terms of morbidity
and mortality (life years gained—LYG) and quantiﬁed
using the UKPDS-36 study (Adler et al, BMJ 2000). Costs
are expressed in €2003. We report undiscounted analysis:
an analysis conducted using a discount rate of 5% for
both costs and effects led to similar results. RESULTS: Cz
+ Dx therapy showed greater efﬁcacy in reducing SBP
compared to both Cz and Dx, leading to lower morbid-
ity and to 231 LYG in the Cz + Dx cohort compared to
Cz and Dx alone. Overall cost was lower for the Cz + Dx
(€61.7 millions) cohort compared to Cz (€74.1 millions)
and Dx (€73.9 millions). CONCLUSIONS: combination
therapy with low dose cilazapril plus low dose doxazosin
dominates both high dose cilazapril and high dose doxa-
zosin in hypertensive diabetic patients in Italy, as it is both
less costly and more effective.
PCV58
ECONOMIC IMPACT OF SELECTED FIXED-
COMBINATION ANGIOTENSIN-CONVERTING
ENZYME INHIBITOR/CALCIUM CHANNEL
BLOCKER ANTI-HYPERTENSIVES AMONG
PATIENTS WITH DIABETES
Joyce AT, Pedan A, Girase PS, Rucker MB, Ollendorf D
PharMetrics Inc, Watertown, MA, USA
OBJECTIVES: Certain combination anti-hypertensives
vary in their levels of potentially adverse metabolic effects
in patients with comorbid diabetes. We examined the
characteristics of patients initiating combination therapy
and the effects of treatment choice on direct medical
costs, using integrated medical and pharmacy claims data.
METHODS: Patients with prior evidence of diabetes who
were newly-treated for hypertension from January 1998
to March 2002 and continuously enrolled for at least 6
months before and after therapy initiation were selected.
Patients were stratiﬁed by initial ﬁxed combination 
treatment (trandolapril/verapamil [TV] vs. benazepril/
amlodipine [BA]). One-year costs of care were examined
following initiation of therapy; costs were categorized 
as cardiovascular-related and all other-related care. 95%
conﬁdence intervals for cost differences were calculated
using nonparametric bootstrapping techniques. RE-
SULTS: The mean age of the sample (n = 174) was 53
years; 47% were female. 22%, 6%, 6%, and 3% of
patients had comorbid diagnoses of hyperlipidemia,
cardiac arrhythmias, other ischemic heart disease, and
myocardial infarction respectively during pre-treatment.
Patients in the TV group had lower cardiovascular-related
cost as compared to the BA group ($2311 vs. $2570,
mean difference: -$259, 95% CI [-$2730, $1438]). Dif-
ferences in cardiovascular-related cost were manifested
primarily in the cardiovascular-related inpatient cost
($615 vs. $1,209 for TV and BA, respectively, mean dif-
ference: -$594, 95% CI [-$2900, $823]). All other-
related costs were considerably lower in the TV group
($5006 vs. $6404, mean difference: -$1397, 95% CI 
[-$9491, $3669]). Patients in the TV group ($7,317) had
lower overall costs as compared to the BA group ($8,974;
mean difference -$1,656, 95% CI [-$12,657, $4,735]).
CONCLUSIONS: Use of ﬁxed combination tran-
dolapril/verapamil therapy among patients with diabetes
is associated with reduced direct medical costs in com-
parison to combination benazepril/amlodipine.
